touchNEUROLOGY had the pleasure of meeting with Tobias Hartmann (Director and Professor of Experimental Neurology, DIDP, Saarland University, Saarbrücken, Germany) to discuss the recent post-hoc analysis of the LipiDiDiet trial data.
Part 1 of our discussion can be found here.
The abstract entitled ‘ADCOMS: A Post-Hoc Analysis Using Data from the 3-Year Lipididiet Trial in Prodromal Alzheimer’s Disease’ was presented at The 15th International Conference for Alzheimer’s & Parkinson’s Diseases (Virtual), March 8-14, 2021.
Questions:
- Could you tell us a little about the LipiDiDiet study and its findings? (0:17)
- What were the aims of your recent post-hoc analysis of the LipiDiDiet trial data? (2:04)
- What has this analysis taught us and what is the clinical significance of these findings? (6:49)
Disclosures: Tobias Hartmann is the Coordinator of LipiDiDiet study; and received a grant for the EU Joint Programme– Neurodegenerative Disease Research (JPND) EURO‐FINGERS.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AD/PD Virtual 2021.
